Scientists reported: “Our results clearly demonstrate that NIDA cannabis samples are substantially genetically different from most commercially available drug-type strains and share a genetic affinity with hemp samples in several of the analyses.”
“Legislative action is necessary in this arena because the DEA has proven time and time again that it is not an honest broker in this process.”
“The reality that most high-schoolers have easier access to cannabis than do our nation’s top scientists is the height of absurdity and an indictment of the current system.”
Updated data provided today by the US Centers for Disease Control reports over 800 cases of acute respiratory distress linked to the use of portable vapor cartridges used to consume certain e-liquids. Of the products tested thus far by the US Food and Drug Administration, about half have identified the presence of Vitamin E acetate.
We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses.
Rather than use these unfortunate incidents as an opportunity to further drive these markets into the shadows, the administration should officially legalize cannabis and empower the FDA to better study, regulate, and oversee these emerging THC and CBD delivery devices — and to create regulatory standards for legal states to follow and enforce.
“For the past three years, the DEA has failed to take any steps to follow through on its promise to facilitate clinical cannabis research, and today’s announcement makes it clear that this foot-dragging will continue,” NORML Executive Director Erik Altieri said.
Members of the US Senate Committee on Agriculture, Nutrition, and Forestry will hear expert testimony next week regarding the production of industrial hemp and hemp-derived products.